Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2021.02.108 http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.02.108 33667698!7923852!33667698     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 105 (ä): 653-655 Nephropedia Template TP {{tp|p=33667698|t=2021. CCR5Delta32 mutations do not determine COVID-19 disease course |pdf=|usr=}}{{33667698}} gab.com Text CCR5Delta32 mutations do not determine COVID-19 disease course JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33667698 #FOAvip OBJECTIVES: To determine the impact of the 32 bp deletion (CCR5Delta32) in the coding region of the C-C chemokine receptor 5 (CCR5) on the risk of contracting SARS-CoV-2 and severe COVID-19. METHODS: Cross-sectional study among stem cell donors registered with DKMS in Germany. Genetic information was linked to self-reported COVID-19 outcome data. Multivariable regression models were fitted to determine the risk of contracting SARS-CoV-2, severe respiratory tract infection (RTI) and respiratory hospitalization. RESULTS: CCR5 information was available for 110 544 donors who were tested at least once for SARS-CoV-2; 5536 reported SARS-CoV-2 infection. For 4758 donors, the COVID-19 disease course was fully evaluable; 498 reported no symptoms, 1227 described symptoms of severe respiratory tract infection, of whom 164 required respiratory hospitalization. The distribution of CCR5Delta32 genotypes (homozygous wild-type vs CCR5Delta32 present) did not differ significantly between individuals with or without SARS-CoV-2 infection (odds ratio (OR) 0.96, 95% CI 0.89-1.03, P = 0.21) nor between individuals with or without symptomatic infection (OR 1.13, 95% CI 0.88-1.45, P = 0.32), severe RTI (OR 1.03, 95% CI 0.88-1.22, P = 0.68) or respiratory hospitalization (OR 1.16, 95% CI 0.79-1.69, P = 0.45). CONCLUSIONS: Our data implicate that CCR5Delta32 mutations do not determine the risk of SARS-CoV-2 infections nor the disease course. TRIAL REGISTRATION: We registered the study with the German Center for Infection Research (https://dzif.clinicalsite.org/de/cat/2099/trial/4361). Twit Text FOAVip CCR5Delta32 mutations do not determine COVID-19 disease course ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33667698 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33667698 #FOAvip English Wikipedia <ref>{{Cite pmid|33667698}}</ref> CCR5Delta32 mutations do not determine COVID-19 disease course #MMPMID33667698 Bernas SN; Baldauf H; Wendler S; Heidenreich F; Lange V; Hofmann JA; Sauter J; Schmidt AH; Schetelig J Int J Infect Dis 2021[Apr]; 105 (ä): 653-655 PMID33667698show ga OBJECTIVES: To determine the impact of the 32 bp deletion (CCR5Delta32) in the coding region of the C-C chemokine receptor 5 (CCR5) on the risk of contracting SARS-CoV-2 and severe COVID-19. METHODS: Cross-sectional study among stem cell donors registered with DKMS in Germany. Genetic information was linked to self-reported COVID-19 outcome data. Multivariable regression models were fitted to determine the risk of contracting SARS-CoV-2, severe respiratory tract infection (RTI) and respiratory hospitalization. RESULTS: CCR5 information was available for 110 544 donors who were tested at least once for SARS-CoV-2; 5536 reported SARS-CoV-2 infection. For 4758 donors, the COVID-19 disease course was fully evaluable; 498 reported no symptoms, 1227 described symptoms of severe respiratory tract infection, of whom 164 required respiratory hospitalization. The distribution of CCR5Delta32 genotypes (homozygous wild-type vs CCR5Delta32 present) did not differ significantly between individuals with or without SARS-CoV-2 infection (odds ratio (OR) 0.96, 95% CI 0.89-1.03, P = 0.21) nor between individuals with or without symptomatic infection (OR 1.13, 95% CI 0.88-1.45, P = 0.32), severe RTI (OR 1.03, 95% CI 0.88-1.22, P = 0.68) or respiratory hospitalization (OR 1.16, 95% CI 0.79-1.69, P = 0.45). CONCLUSIONS: Our data implicate that CCR5Delta32 mutations do not determine the risk of SARS-CoV-2 infections nor the disease course. TRIAL REGISTRATION: We registered the study with the German Center for Infection Research (https://dzif.clinicalsite.org/de/cat/2099/trial/4361). |*Sequence Deletion[MESH] |Adolescent[MESH] |Adult[MESH] |COVID-19/*genetics/physiopathology[MESH] |Cross-Sectional Studies[MESH] |Disease Progression[MESH] |Female[MESH] |Genotype[MESH] |Germany[MESH] |Hospitalization[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Odds Ratio[MESH] |Receptors, CCR5/*genetics[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH] |Self Report[MESH]CCR5Delta32 mutations do not determine COVID-19 disease course (epmc).pdf DeepDyve Pubget Overpricing